Medicxi has created an “ideas factory” to boost its capacity to turn early-stage science into pipelines of drug candidates and startups to develop them. The VC fund is setting up the venture with its CSO, David Grainger, Ph.D., and Johnson & Johnson’s Richard Mason, M.D.
Anglo-Swiss investment group Medicxi made its name creating biotechs and taking them to key data readouts on lean budgets. Medicxi has since broadened its scope, notably by adding a late-phase fund, but helping researchers turn scientific insights into drug assets remains central to its business. Setting up The Foundation Institute for 21st Century Medicine, abbreviated to C21Med, is intended to further these activities.
https://www.fiercebiotech.com/biotech/medicxi-founds-biotech-creation-engine-c21med